Health
Platform to predict future AF/atrial flutter nets breakthrough device designation – Healio
Tempus announced the FDA has granted a breakthrough device designation to its ECG analysis platform for the identification of atrial fibrillation or atrial flutter,…
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected] to Healio
Tempus announced the FDA has granted a breakthrough device designation to its ECG analysis platform for the identification of atrial fibrillation or atrial flutter, developed in collaboration with Geisinger.
The platform (Tempus ECG Analysis Platform, Tempus and Geisinger) is designated for use in patients aged 40 years and older who do not…
-
Noosa News12 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News20 hours agoDifficult to diagnose and potentially deadly — this lesser-known disease is becoming more common
-
Noosa News20 hours agoCountdown on for Noosa Eat & Drink Festival 2025
-
Noosa News17 hours agoBrisbane news live: Federal fund for council’s cyclone clean-up dries up